Rory Hunter: SGH Medical Technology Fund June 2024 Quarterly Update

Investment strategy

The Investment Manager seeks to achieve long-term capital growth by focusing stock selection on:

1. Share valuation
2. Company management and industry structure
3. Behavioural factors to determine investment-timing

It is intended that the investment portfolio will consist of 40 to 60 companies split between:
Mature Growth – companies that have established medical products, generate revenue and are profitable. Typically, the medical technology is hard to disrupt or replicate and has a leading market position, e.g. CSL Limited.

Developing Growth – companies that have disruptive intellectual property in the medical technology space. Typically, these companies are in late-stage clinical trials or have registered or approved medical products, growing market access, and early-stage revenue.

Seed – companies that are involved in drug discovery, clinical trials or disruptive medical technology, e.g., start-ups. Typically, these are fast-growing and highly innovative companies with exponential growth potential from successful medical product commercialisation.

Unlisted and pre-Initial Public Offering (IPO) companies – these companies will typically reside in the “Seed” and “Developing Growth” stage of their life-cycle as defined above.

HOW TO INVEST

Existing SGH or DMP investor with Apex investor number:

1. Download and read PDS, reference guide and Target Market Determination (TMD).
2. Complete additional investment form and send to Apex Fund Services Unit Registry.

Please contact Apex Fund Services at 1300 133 451 if you require assistance.

Not an existing SGH or DMP investor:

1. Download and read PDS, reference guide and Target Market Determination (TMD).
2. Submit application form online.

OR

1. Download and read PDS, reference guide and Target Market Determination (TMD).
2. Complete an application form and send to Apex Fund Services Unit Registry.